You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

relapsed

Showing 51 - 75 of 7,775
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed/Refractory Non-Hodgkin Lymphoma Trial in Duarte, Amsterdam (BMS-986458, Rituximab)

Not yet recruiting
  • Relapsed/Refractory Non-Hodgkin Lymphoma
  • Duarte, California
  • +1 more
Oct 13, 2023

Relapsed/Refractory Acute Myeloid Leukemia Trial in Hangzhou (B7-H3 target, CAR gene modified gdT cell injection)

Recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia
  • B7-H3 target, CAR gene modified gdT cell injection
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital， Zhejiang University School of Med
Feb 15, 2023

T-lymphoblastic Lymphoma, T-ALL Trial in Shanghai (CAR-T)

Recruiting
  • T-lymphoblastic Lymphoma
  • T-ALL
  • CAR-T
  • Shanghai, China
    Shanghai Ruijin Hospital
Nov 14, 2023

Mantle-cell Lymphoma Trial (Polatuzumab, bendamustin und rituximab)

Not yet recruiting
  • Mantle-cell Lymphoma
  • Polatuzumab, bendamustin und rituximab
  • (no location specified)
May 11, 2023

Relapsed or Refractory B-cell Lymphoma Trial in Shanghai (SR-GDP)

Not yet recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • Shanghai, Shanhai, China
    Ruijin Hospital
Sep 29, 2023

Relapsed or Refractory Multiple Myeloma Trial (Cevostamab, Elranatamab, Tocilizumab)

Not yet recruiting
  • Relapsed or Refractory Multiple Myeloma
  • (no location specified)
Jun 22, 2023

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Venetoclax)

Not yet recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • (no location specified)
Oct 30, 2023

Relapsed Solid Tumor, Refractory Cancer, Solid Tumor, Adult Trial (STI-3258)

Withdrawn
  • Relapsed Solid Neoplasm
  • +2 more
  • STI-3258
  • (no location specified)
Jan 24, 2023

Relapsed or Refractory B Cell Non-Hodgkin Lymphoma Trial (C-CAR066)

Not yet recruiting
  • Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
  • (no location specified)
Mar 23, 2023

Refractory Solid Tumors Trial in Houston (Eribulin, Irinotecan, Temozolomide)

Recruiting
  • Refractory Solid Tumors
  • Houston, Texas
    M D Anderson Cancer Center
Aug 22, 2023

Relapsed/Refractory Acute Myeloid Leukemia Trial in Hefei (gdT cell injection targeting B7-H3 chimeric antigen receptor)

Recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia
  • gdT cell injection targeting B7-H3 chimeric antigen receptor
  • Hefei, Anhui, China
    PersonGen Anke Cellular Therapeutice Co., Ltd.
Jan 31, 2023

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission Trial in São Paulo (Bortezomib)

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • Acute Lymphoblastic Leukemia With Failed Remission
  • São Paulo, SP, Brazil
    Instituto do Cancer do Estado de Sao Paulo
Sep 12, 2023

Bortezomib, Acute Myeloid Leukemia Trial in Wuhan (DAG pre-excitation regimen with Bortezomib)

Recruiting
  • Bortezomib
  • Acute Myeloid Leukemia
  • DAG pre-excitation regimen with Bortezomib
  • Wuhan, Hubei, China
    Zhongnan Hospital of Wuhan University
Jul 31, 2023

Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Advanced Solid Tumor Trial (TR115)

Not yet recruiting
  • Non-Hodgkin's Lymphoma, Relapsed
  • +2 more
  • (no location specified)
Dec 6, 2022

AML/MDS, Acute Myeloid Leukemia, MDS Trial (Danvatirsen, Danvatirsen + Venetoclax)

Not yet recruiting
  • AML/MDS
  • +2 more
  • (no location specified)
Aug 14, 2023

Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
  • (no location specified)
Sep 5, 2023

Warm Autoimmune Hemolytic Anemia Trial in Beijing (Sirolimus)

Not yet recruiting
  • Warm Autoimmune Hemolytic Anemia
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Jun 21, 2023

Large Cell Lymphoma, Diffuse, Relapsed Cancer, Refractory Cancer Trial (AutoSCT, GDP, Epcoritamab)

Not yet recruiting
  • Large Cell Lymphoma, Diffuse
  • +2 more
  • AutoSCT
  • +2 more
  • (no location specified)
May 10, 2023

Belantamab Mafodotin Care Patterns in Relapsed and/or Refractory

Not yet recruiting
  • Multiple Myeloma
  • Durham, North Carolina
    Duke University Medical Center
Aug 8, 2023

Extensive Stage Small Cell Lung Cancer Trial (hSTC810 400 mg + Paclitaxel, hSTC810 800 mg + Paclitaxel)

Not yet recruiting
  • Extensive Stage Small Cell Lung Cancer
  • hSTC810 400 mg + Paclitaxel
  • hSTC810 800 mg + Paclitaxel
  • (no location specified)
Aug 24, 2023

Acute Myeloid Leukemia Trial in Beijing (Ven+CAG)

Recruiting
  • Acute Myeloid Leukemia
  • Beijing, Beijing, China
    Peking University People's Hospital
Jun 23, 2023

Lymphoma Trial in Yerevan (Balstilimab)

Not yet recruiting
  • Lymphoma
  • Yerevan, Armenia
    Hematology Center named after prof. R. Yeolyan
May 26, 2023

Relapsed/Refractory Lymphoma Trial in Shanghai (tazemetostat, HMPL-689)

Not yet recruiting
  • Relapsed/Refractory Lymphoma
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Feb 2, 2023

Relapsed or Refractory Acute Myeloid Leukemia Trial in Taiyuan (Selinexor, Homoharringtonine, Daunorubicin)

Recruiting
  • Relapsed or Refractory Acute Myeloid Leukemia
  • Taiyuan, Shanxi, China
    Tao Wang
Feb 9, 2023

Relapsed/Refractory Diffuse Large B Cell Lymphoma Trial in Seoul (Glofitamab, Poseltinib, Lenalidomide)

Recruiting
  • Relapsed/Refractory Diffuse Large B Cell Lymphoma
  • Glofitamab, Poseltinib, Lenalidomide
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Nov 28, 2022